Stock listing
NASDAQ:ADRX ADARx Pharmaceuticals, Inc. Stock
Home listing (NASDAQ) of ADARx Pharmaceuticals, Inc.
Follow ADARx Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ADRX
$12.79 USD -0.03 (-0.2%)
Close on Nov 20, 2026
- Day range
- $12.66 – $14.86 USDNov 20, 2026
- Volume
- 708,823 sharesNov 20, 2026
- Market cap
- $1.42B USDAt the close on Nov 20, 2026 · price × 110.7M shares outstanding
- Traded on an average day
- $11.31M USDMedian day 475,714 shares · last 3 months, Sep 25, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ADRX · Home | $12.79 USD | -0.03 (-0.2%) | 708,823 | $14.03 | $14.86 | $12.66 | $12.82 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Sep 25, 2026 – Nov 20, 2026 · NASDAQ:ADRX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $12.79 | -0.03 | -0.2% | $14.03 | $14.86 | $12.66 | 708,823 | |
| $12.82 | -1.00 | -7.2% | $13.85 | $14.84 | $12.79 | 654,561 | |
| $13.82 | -0.18 | -1.3% | $14.03 | $14.96 | $12.90 | 696,893 | |
| $14.00 | -0.20 | -1.4% | $14.22 | $15.21 | $13.08 | 667,015 | |
| $14.20 | -0.71 | -4.8% | $14.96 | $15.21 | $13.70 | 587,958 | |
| $14.91 | +1.61 | +12.1% | $13.25 | $16.24 | $12.87 | 994,874 | |
| $13.30 | -0.27 | -2.0% | $13.73 | $14.07 | $13.17 | 509,927 | |
| $13.57 | -0.23 | -1.7% | $13.64 | $14.30 | $13.30 | 289,825 | |
| $13.80 | +0.57 | +4.3% | $13.24 | $13.99 | $12.70 | 357,025 | |
| $13.23 | -0.06 | -0.5% | $13.73 | $13.73 | $12.50 | 439,977 | |
| $13.29 | -1.67 | -11.2% | $14.97 | $15.39 | $12.75 | 781,163 | |
| $14.96 | -1.13 | -7.0% | $16.33 | $16.73 | $14.85 | 377,795 | |
| $16.09 | +0.33 | +2.1% | $15.78 | $16.46 | $15.00 | 378,482 | |
| $15.76 | -1.24 | -7.3% | $16.95 | $17.01 | $15.71 | 378,575 | |
| $17.00 | -0.85 | -4.8% | $18.10 | $18.10 | $16.30 | 542,258 | |
| $17.85 | -0.10 | -0.6% | $18.00 | $18.75 | $17.65 | 402,000 | |
| $17.95 | -0.18 | -1.0% | $18.22 | $18.36 | $17.66 | 264,700 | |
| $18.13 | +0.32 | +1.8% | $17.99 | $18.80 | $17.71 | 293,600 | |
| $17.81 | +0.18 | +1.0% | $17.77 | $19.07 | $17.50 | 99,600 | |
| $17.63 | -0.05 | -0.3% | $17.68 | $18.33 | $17.00 | 177,600 | |
| $17.68 | +0.55 | +3.2% | $17.18 | $17.88 | $17.18 | 181,500 | |
| $17.13 | -0.55 | -3.1% | $17.58 | $18.17 | $17.00 | 441,500 | |
| $17.68 | +0.05 | +0.3% | $17.98 | $18.55 | $16.61 | 1,074,900 | |
| $17.63 | -0.02 | -0.1% | $17.76 | $18.33 | $17.05 | 262,000 | |
| $17.65 | -0.05 | -0.3% | $17.73 | $18.60 | $17.50 | 247,100 | |
| $17.70 | -0.13 | -0.7% | $17.75 | $18.33 | $17.50 | 283,400 | |
| $17.83 | +0.13 | +0.7% | $17.72 | $18.28 | $17.31 | 285,500 | |
| $17.70 | -0.27 | -1.5% | $18.00 | $18.82 | $17.57 | 221,000 | |
| $17.97 | +0.19 | +1.1% | $17.78 | $18.75 | $17.57 | 350,800 | |
| $17.78 | +0.10 | +0.6% | $17.70 | $18.19 | $17.06 | 688,500 | |
| $17.68 | +0.35 | +2.0% | $17.13 | $18.10 | $16.64 | 420,200 | |
| $17.33 | -1.25 | -6.7% | $18.33 | $18.70 | $17.20 | 705,600 | |
| $18.58 | -0.47 | -2.5% | $19.05 | $19.57 | $18.01 | 1,034,900 | |
| $19.05 | +0.80 | +4.4% | $18.25 | $19.40 | $17.30 | 913,900 | |
| $18.25 | -1.29 | -6.6% | $19.31 | $19.53 | $17.85 | 937,000 | |
| $19.54 | -0.40 | -2.0% | $19.99 | $20.77 | $18.99 | 962,200 | |
| $19.94 | -0.70 | -3.4% | $20.65 | $21.61 | $19.23 | 788,800 | |
| $20.64 | +0.55 | +2.7% | $19.90 | $21.50 | $19.51 | 1,299,400 | |
| $20.09 | +0.74 | +3.8% | $19.00 | $21.77 | $18.50 | 1,205,200 | |
| $19.35 | — | — | $22.10 | $23.21 | $19.00 | 4,213,100 |
- Ticker
- NASDAQ:ADRX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates
Latest deck · Nov 12, 2026
Corporate Update (November 2026)
Corporate update · 33 slides
Latest news
ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates
Nov 12, 2026
Closed $14.20 (-4.8%) on Nov 13, 2026
ADARx Pharmaceuticals to Present at the UBS Global Biopharma Conference
Nov 9, 2026
Closed $13.80 (+4.3%) on Nov 9, 2026
ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering
Oct 1, 2026
Closed $18.25 (-6.6%) on Oct 2, 2026
ADARx Pharmaceuticals surges following upsized IPO
Sep 25, 2026
Closed $20.09 (+3.8%) on Sep 28, 2026
ADARx Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 4 in the last 12 months · 4 in all · newest Nov 12, 2026 · oldest 2026
- Decks
- 2 decks · latest Nov 12, 2026
Where ADARx Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ADRX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ADRX | BOATS | United States | USD |
Valuation
EV/sales 77.6× against a median of 9.5×: 6th lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $521.8M USD
- P/E
- Loss
- EV/sales
- 77.6×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.5×
- Gross margin
- −231.0%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- Under 6 months of closes
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| ADARx Pharmaceuticals, Inc. · NASDAQ:ADRX | US$1.42B | US$521.8M | n/a | 77.6× | n/a | 2.5× | n/a | 0.0× | n/a |
| Mesoblast Limited · ASX:MSB | US$1.46B | US$1.42B | n/a | 82.4× | n/a | 2.4× | −593.9% | 0.2× | n/a |
| Voronoi, Inc. · KRX:310210 | US$1.44B | US$1.40B | n/a | n/a | n/a | 27.9× | n/a | 0.5× | n/a |
| Damora Therapeutics, Inc. · NASDAQ:DMRA | US$1.44B | US$910.0M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | 0.88 |
| Vir Biotechnology, Inc. · NASDAQ:VIR | US$1.44B | US$1.07B | n/a | 3.5× | n/a | 1.6× | −61.0% | 0.1× | 1.82 |
| LigaChem Biosciences Inc. · KRX:141080 | US$1.43B | US$1.15B | n/a | 15.5× | n/a | 4.8× | −180.9% | 0.0× | n/a |
| Kailera Therapeutics, Inc. · NASDAQ:KLRA | US$1.43B | US$539.5M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 1.28 |
| Sarepta Therapeutics, Inc. · NASDAQ:SRPT | US$1.43B | US$1.41B | n/a | 0.7× | n/a | 0.9× | −5.9% | 0.6× | 1.70 |
| Nurix Therapeutics, Inc. · NASDAQ:NRIX | US$1.40B | US$683.6M | 4.8× | 1.0× | n/a | 1.4× | 42.0% | 0.0× | 1.15 |
| Intellia Therapeutics, Inc. · NASDAQ:NTLA | US$1.40B | US$1.00B | n/a | 19.0× | n/a | 2.3× | −805.7% | 0.1× | 2.01 |
| Tyra Biosciences, Inc. · NASDAQ:TYRA | US$1.39B | US$694.9M | n/a | n/a | n/a | 2.0× | n/a | 0.0× | 0.40 |
| Median of the others | US$1.43B | US$1.04B | 4.8× | 9.5× | 2.1× | −121.0% | 0.1× | 1.28 |
Forecasts
3 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 34.25 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.01 · 3 analysts
- Revenue, year to Dec 2026
- 6.53M · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Zhen Li | President & CEO |
| Ryan Fisk | Chief Financial Officer and Chief Business Officer |
| Christopher Claeboe | Senior Vice President of Operations |
| Mary Tagliaferri | Chief Medical Officer and SVP at Nektar Therapeutics |
| Carl Gordon | Co-head Global Private Equity at OrbiMed Advisors |
| Rob Ackles | Chief People Officer |
| Robert A. MacLeod | Chief Scientific Officer |
| Rui Zhu | Chief Technology Officer |
Board
| Director | Role |
|---|---|
| Carl Gordon | Co-head Global Private Equity at OrbiMed Advisors |
| Erez Chimovits | Partner at OrbiMed Advisors |
| Mary Tagliaferri | Chief Medical Officer and SVP at Nektar Therapeutics |
| Simeon George | Director |
| Ying Huang | Board Member |
| Zhen Li | President & CEO |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | −4.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (November 2026) | Corporate update | 33 slides | Nov 12, 2026 |
| IPO Roadshow (September 2026) | IPO roadshow | 35 slides | September 2026 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$17 a share · J.P. Morgan +4 Dealers: J.P. Morgan (co-lead), Morgan Stanley (co-lead), TD Cowen (co-lead), UBS Investment Bank (co-lead), LifeSci Capital | Oct 1, 2026 |
| Private placement of common stock Closed: US$17 a share Buyers: AbbVie (5,255,542 shares of common stock at $17.00 per share) | Oct 1, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$17.00 a share on Sep 24, 2026.
- Price
- US$17.00 a share
- Shares offered
- 26,250,000 shares of common stock
- Offering size
- US$446.3 million
- Underwriters' option
- Up to 3,937,500 more shares
- Listing
- ADRX on the Nasdaq Global Select Market
- Underwriters
- J.P. Morgan, Morgan Stanley, TD Cowen, UBS Investment Bank, LifeSci Capital · In the order on the cover
- Shares delivered
- On or about Sep 28, 2026
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jun 22, 2026 |
| Filed publicly | Sep 4, 2026 |
| Amended twice | Newest Sep 21, 2026 |
| Shares registered with an exchange | Sep 22, 2026 |
| Declared effective by the SEC | Sep 24, 2026 |
| Final prospectus, with the price | Sep 28, 2026 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Sep 28, 2026 |
| EFFECT · Notice that a registration is effective | Sep 24, 2026 |
| S-1MEF · Registration of more shares for the same offering | Sep 24, 2026 |
| CERT · Exchange's certificate of listing | Sep 24, 2026 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 22, 2026 |
| S-1/A · Registration statement, amended | Sep 21, 2026 |
| S-1/A · Registration statement, amended | Sep 14, 2026 |
| S-1 · Registration statement | Sep 4, 2026 |
| DRS/A · Draft registration statement, amended | Jul 31, 2026 |
| DRS · Draft registration statement | Jun 22, 2026 |
Open IPO · From the cover of the final prospectus (424B4) filed Sep 28, 2026
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | 3.45M | 0 |
| Gross profit | 3.45M | |
| Research and development | 71.5M | 43.4M |
| Selling, general and administrative | 20.3M | 14.9M |
| Operating income | -88.4M | -58.2M |
| Depreciation and amortization | 2.33M | 1.50M |
| EBITDA | -86.0M | -56.7M |
| Income before tax | -73.1M | -46.4M |
| Net income | -73.1M | -46.4M |
| Earnings per share, basic | -0.97 | -0.45 |
Balance sheet
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash and equivalents | 66.5M | 14.0M |
| Short-term investments | 413.5M | 205.4M |
| Current assets | 493.4M | 225.7M |
| Total assets | 507.7M | 233.5M |
| Accounts payable | 5.84M | 1.35M |
| Current liabilities | 30.5M | 8.94M |
| Total debt | 7.74M | |
| Total liabilities | 709.9M | 370.6M |
| Shareholders' equity | -202.3M | -137.1M |
| Shares outstanding | 75.3M | 102.2M |
Cash flow
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash from operations | 262.3M | -48.6M |
| Capital spending | -2.94M | -455.0K |
| Free cash flow | 259.4M | -49.0M |
| Cash from investing | -209.9M | |
| Cash from financing | 97.0K | 225.0K |
| Change in cash | 52.5M | -8.82M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Oct 5, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Oct 2, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 1, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2026 | Insider trade | SEC |
All 51 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Sep 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Sep 28, 2026 | Offer document | SEC |
| 4 · Change in ownership | Sep 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 28, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 28, 2026 | Financing | SEC |
| 424B4 · Prospectus | Sep 25, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 25, 2026 | Other filings | SEC |
| 3 · Initial statement of ownership | Sep 24, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 24, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 24, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 24, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 24, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 24, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 24, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 24, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 24, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 24, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 24, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 24, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 24, 2026 | Insider trade | SEC |
| S-1MEF · Registration of more shares for the same offering | Sep 24, 2026 | Offer document | SEC |
| CERT · Exchange's certificate of listing | Sep 24, 2026 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Sep 22, 2026 | Other filings | SEC |
| S-1/A · Registration statement, amended | Sep 21, 2026 | Offer document | SEC |
| S-1/A · Registration statement, amended | Sep 14, 2026 | Offer document | SEC |
| S-1 · Registration statement | Sep 4, 2026 | Offer document | SEC |
| DRS/A · Draft registration statement, amended | Jul 31, 2026 | Offer document | SEC |
| DRS · Draft registration statement | Jun 22, 2026 | Offer document | SEC |
| D | Aug 10, 2023 | Other filings | SEC |
| D | Jan 26, 2023 | Other filings | SEC |
| D | Aug 17, 2021 | Other filings | SEC |
| D | May 21, 2021 | Other filings | SEC |
| D | Nov 16, 2020 | Other filings | SEC |
| D | Aug 6, 2020 | Other filings | SEC |
| D | Feb 5, 2020 | Other filings | SEC |
Cap table
Built by 6ix from ADARx Pharmaceuticals, Inc.’s releases · as of Oct 1, 2026
- Common shares
- 110,738,825
- Fully diluted
- 110,738,825
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 110,738,825 | Oct 1, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 110,738,825 |
| Oct 1, 2026 | 116,449,005 |
| Oct 1, 2026 | 111,193,463 |
| Sep 30, 2026 | 107,255,963 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Simeon George Other companies: Design Therapeutics, Inc. (Director · Since at least Jun 15, 2022); CRISPR Therapeutics AG (Director · Since at least Jun 9, 2022); Nkarta, Inc. (Director · Since at least Apr 28, 2022); Turning Point Therapeutics Inc (Director · Aug 17, 2022 – Aug 17, 2022 · Past) | Director · Since at least Sep 24, 2026 |
| Mary Tagliaferri Other companies: Y mAbs Therapeutics (Director · Feb 29, 2024 – Jun 11, 2024 · Past); RayzeBio, Inc. (Director · Sep 14, 2023 – Feb 26, 2024 · Past); Enzo Biochem Inc (Director · Nov 17, 2020 – Jan 31, 2024 · Past) | Chief Medical Officer and SVP at Nektar Therapeutics · Since at least Sep 24, 2026 |
| Carl L. Gordon Other companies: Electra Therapeutics, Inc. (Director · Since at least Sep 21, 2026); BlossomHill Therapeutics, Inc. (Director · Since at least Aug 10, 2026) | Director · Since at least Sep 28, 2026 |
| Ying Huang Other companies: TCGX Acquisition Corp. (Director · Since at least Aug 4, 2026); Legend Biotech Corp. (Chief Executive Officer, Director · Since at least Mar 18, 2026) | Board Member · Since at least Sep 24, 2026 |
| Erez Chimovits Other companies: Braveheart Bio, Inc. (Director · Since at least Aug 7, 2026) | Director · Since at least Sep 28, 2026 |
| Alan Robert MacLeod | Chief Scientific Officer · Since at least Sep 24, 2026 |
| Christopher Claeboe | Senior Vice President of Operations · Since at least Nov 4, 2026 |
| Rob Ackles | Chief People Officer · Since at least Nov 4, 2026 |
| Robert A. MacLeod | Chief Scientific Officer · Since at least Nov 4, 2026 |
| Robert William Ackles | Chief People Officer · Since at least Sep 24, 2026 |
All 13 people
| Person | Seat |
|---|---|
| Rui Zhu | Chief Technology Officer · Since at least Sep 24, 2026 |
| Ryan Fisk | CFO and CBO · Since at least Sep 24, 2026 |
| Zhen Li | President and CEO, Director · Since at least Sep 24, 2026 |
Log in to ask 6ix AI your own questions about ADARx Pharmaceuticals, Inc.